Loading…
Loading…
BXPHF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BXPHF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BXPHF and 80,000+ other tickers.
See exactly how BXPHF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BXPHF and 80,000+ other tickers.
Botanix Pharmaceuticals Ltd is a dermatology company that focuses on developing safe and effective topical treatments for serious skin conditions. The company's product pipeline includes treatments for conditions such as moderate to severe acne, atopic dermatitis, rosacea, and axillary hyperhidrosis. It has an exclusive license to use a proprietary drug delivery system for skin diseases.
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis Transcript
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Sofdra Update Transcript
Botanix Pharmaceuticals Limited (BXPHF) Q2 2026 Earnings Call Transcript